nct_id,last_update_submitted_date,registration_date,summary_results_date,study_type,phase,enrollment,recruitment_status,title,start_date,completion_date,primary_completion_date,has_summary_results,allocation,masking,main_sponsor,is_multicentric
NCT00493298,2023-01-23,2007-06-27,NA,Observational,NA,6620,"Active, not recruiting",Tysabri Observational Program,2007-06-29T00:00:00Z,2029-01-03T00:00:00Z,2029-01-03T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT00887146,2023-10-30,2009-04-22,NA,Interventional,Phase 3,360,Recruiting,Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma,2009-09-01T00:00:00Z,2025-10-01T00:00:00Z,2025-10-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE
NCT01139892,2023-07-04,2010-06-02,NA,Observational,NA,291,Completed,The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES),2010-09-26T00:00:00Z,2022-10-01T00:00:00Z,2022-10-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT01194570,2023-05-19,2010-08-28,2017-03-30,Interventional,Phase 3,735,Completed,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2011-03-02T00:00:00Z,2022-12-31T00:00:00Z,2015-07-23T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE
NCT01349582,2023-07-04,2011-05-04,NA,Interventional,Not Applicable,323,Completed,Flow Diversion in Intracranial Aneurysm Treatment,2011-05-02T00:00:00Z,2023-01-01T00:00:00Z,2023-01-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE
NCT01412333,2023-03-02,2011-08-08,2017-03-30,Interventional,Phase 3,835,Completed,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2011-09-20T00:00:00Z,2022-12-30T00:00:00Z,2015-05-12T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT01442194,2021-12-28,2011-08-21,NA,Observational,NA,3076,Completed,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,2011-08-01T00:00:00Z,2020-07-10T00:00:00Z,2020-07-10T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT01665144,2023-10-13,2012-08-03,2018-08-06,Interventional,Phase 3,1651,Completed,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),2012-12-20T00:00:00Z,2023-03-30T00:00:00Z,2016-04-29T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE
NCT01960348,2018-11-18,2013-10-09,2018-08-07,Interventional,Phase 3,225,Completed,"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",2013-11-01T00:00:00Z,2017-08-01T00:00:00Z,2017-08-01T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE
NCT02098252,2023-07-04,2014-03-25,NA,Interventional,Not Applicable,1000,Recruiting,Treatment of Brain AVMs (TOBAS) Study,2014-05-01T00:00:00Z,2036-01-01T00:00:00Z,2035-01-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE
NCT02255656,2022-03-21,2014-09-30,2021-06-30,Interventional,Phase 4,1062,Completed,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,2015-01-07T00:00:00Z,2020-07-15T00:00:00Z,2020-07-15T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT02388165,2020-12-11,2015-03-09,2020-06-05,Interventional,Phase 2,3450,Terminated,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation,2015-07-02T00:00:00Z,2019-06-27T00:00:00Z,2019-06-26T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT02398656,2022-05-16,2015-03-20,NA,Interventional,Phase 3,1274,Recruiting,A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion,2015-04-01T00:00:00Z,2024-12-01T00:00:00Z,2024-12-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT02414165,2020-02-06,2015-04-03,NA,Interventional,Phase 2/Phase 3,403,Terminated,The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma,2015-11-30T00:00:00Z,2019-12-20T00:00:00Z,2019-05-31T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT02485600,2021-06-23,2015-06-26,NA,Observational,NA,88,Completed,Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients,2015-10-19T00:00:00Z,2020-02-26T00:00:00Z,2020-02-26T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT02547818,2021-11-08,2015-09-10,NA,Interventional,Phase 3,620,Completed,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,2015-09-15T00:00:00Z,2020-11-18T00:00:00Z,2020-11-13T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT02623699,2023-07-07,2015-11-24,2023-05-17,Interventional,Phase 3,176,Completed,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",2016-01-20T00:00:00Z,2021-07-16T00:00:00Z,2021-07-16T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT02638207,2021-01-28,2015-12-16,2020-09-03,Interventional,Phase 3,142,Completed,Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy,2017-09-27T00:00:00Z,2019-09-05T00:00:00Z,2019-09-05T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT02655614,2020-08-04,2016-01-07,NA,Interventional,Phase 1,54,Completed,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",2016-05-31T00:00:00Z,2020-03-16T00:00:00Z,2020-03-16T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT02667587,2023-11-03,2016-01-26,2021-11-30,Interventional,Phase 3,716,"Active, not recruiting","An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",2016-05-09T00:00:00Z,2024-02-19T00:00:00Z,2020-12-22T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT02685605,2023-05-09,2016-02-05,NA,Interventional,Phase 3,314,Recruiting,Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme,2016-12-09T00:00:00Z,2024-03-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE
NCT02688985,2023-08-28,2016-02-18,NA,Interventional,Phase 3,132,Completed,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),2016-04-29T00:00:00Z,2023-04-11T00:00:00Z,2023-04-11T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT02782741,2023-06-01,2016-05-23,2021-03-12,Interventional,Phase 3,100,Completed,Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease,2016-11-02T00:00:00Z,2023-05-31T00:00:00Z,2020-03-19T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT02792218,2021-09-03,2016-06-02,2020-09-18,Interventional,Phase 3,930,Completed,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2016-09-20T00:00:00Z,2020-07-20T00:00:00Z,2019-07-05T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT02796261,2022-01-19,2016-06-03,NA,Interventional,Phase 3,343,"Active, not recruiting",Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients,2016-07-01T00:00:00Z,2023-06-01T00:00:00Z,2023-06-01T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT02906020,2022-05-03,2016-09-14,2021-12-16,Interventional,Phase 2,273,Terminated,"A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation",2016-12-15T00:00:00Z,2021-05-27T00:00:00Z,2020-12-18T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT02927080,2022-09-14,2016-10-05,2020-09-18,Interventional,Phase 2,95,Terminated,Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD),2016-11-01T00:00:00Z,2019-10-09T00:00:00Z,2019-09-17T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03044249,2021-03-05,2017-01-31,2021-01-29,Interventional,Phase 2,81,Terminated,A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression,2017-05-04T00:00:00Z,2020-01-30T00:00:00Z,2020-01-30T00:00:00Z,TRUE,Randomized,Triple,OTHER,TRUE
NCT03068754,2020-09-18,2017-02-23,2020-08-14,Interventional,Phase 2/Phase 3,143,Terminated,Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),2017-06-22T00:00:00Z,2019-11-25T00:00:00Z,2019-11-25T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE
NCT03070119,2023-05-19,2017-02-28,NA,Interventional,Phase 3,138,"Active, not recruiting",Long-Term Evaluation of BIIB067 (Tofersen),2017-03-08T00:00:00Z,2024-06-13T00:00:00Z,2024-06-13T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE
NCT03083665,2023-11-08,2017-02-28,2022-12-15,Interventional,Phase 3,449,Completed,A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy,2017-08-22T00:00:00Z,2022-06-30T00:00:00Z,2022-06-30T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03085810,2023-10-23,2017-03-16,NA,Interventional,Phase 3,1239,Completed,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2017-03-24T00:00:00Z,2023-04-27T00:00:00Z,2023-04-27T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT03090789,2023-09-26,2017-03-10,NA,Observational,NA,2000,Recruiting,FA Clinical Outcome Measures,2001-01-01T00:00:00Z,2030-01-01T00:00:00Z,2030-01-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT03098511,2023-05-03,2017-03-22,NA,Interventional,Not Applicable,333,"Active, not recruiting",CT-Perfusion for Neurological Diagnostic Evaluation,2017-04-25T00:00:00Z,2023-08-31T00:00:00Z,2023-08-31T00:00:00Z,FALSE,NA,None (Open Label),OTHER,TRUE
NCT03160898,2020-08-21,2017-05-12,2020-08-05,Interventional,Phase 2,458,Completed,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",2017-07-24T00:00:00Z,2019-03-07T00:00:00Z,2019-03-07T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03179501,2018-10-18,2017-06-05,NA,Interventional,Phase 1,4,Terminated,"NP001, Alzheimer's Disease, and Blood Markers of Inflammation",2017-09-01T00:00:00Z,2018-07-31T00:00:00Z,2018-07-31T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,FALSE
NCT03186989,2023-02-16,2017-06-06,NA,Interventional,Phase 1/Phase 2,46,Completed,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",2017-10-12T00:00:00Z,2022-05-13T00:00:00Z,2022-05-12T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT03192332,2023-03-06,2017-06-12,NA,Interventional,Not Applicable,410,Completed,Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke,2017-11-29T00:00:00Z,2021-08-11T00:00:00Z,2021-05-14T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT03260920,2023-10-04,2017-07-19,NA,Interventional,Phase 2,112,"Active, not recruiting",Intranasal Oxytocin for Frontotemporal Dementia,2018-01-31T00:00:00Z,2024-12-31T00:00:00Z,2023-06-30T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,TRUE
NCT03309579,2023-04-20,2017-10-10,NA,Interventional,Not Applicable,740,Recruiting,SAHaRA: A Randomized Controlled Trial,2018-02-12T00:00:00Z,2024-09-01T00:00:00Z,2023-09-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT03315130,2022-07-26,2017-10-16,2022-05-31,Interventional,Phase 2,45,Completed,Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis,2017-10-11T00:00:00Z,2020-11-19T00:00:00Z,2018-12-10T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03318523,2022-02-15,2017-10-19,2021-10-25,Interventional,Phase 2,357,Terminated,"Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease",2018-01-10T00:00:00Z,2021-04-29T00:00:00Z,2020-10-26T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03362658,2023-01-24,2017-10-18,NA,Observational,NA,700,Recruiting,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,2016-10-01T00:00:00Z,2023-12-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT03364036,2023-02-20,2017-12-01,2021-05-04,Interventional,Phase 4,270,Completed,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2018-05-28T00:00:00Z,2022-02-21T00:00:00Z,2020-05-05T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT03402919,2019-10-02,2018-01-11,NA,Observational,NA,2300,Unknown status,Comprehensive Assessment of Neurodegeneration and Dementia,2016-06-01T00:00:00Z,2023-09-01T00:00:00Z,2023-09-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT03478982,2021-02-02,2018-03-07,2020-12-16,Interventional,Phase 2,156,Completed,"Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern",2018-03-16T00:00:00Z,2020-01-04T00:00:00Z,2019-12-22T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03504917,2021-10-26,2018-04-12,2021-03-02,Interventional,Phase 3,322,Terminated,A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension,2018-08-08T00:00:00Z,2020-07-01T00:00:00Z,2020-03-04T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE
NCT03505021,2022-04-22,2018-04-16,2021-07-01,Interventional,Phase 3,496,Completed,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,2018-06-21T00:00:00Z,2020-07-23T00:00:00Z,2020-07-23T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03529045,2023-05-22,2018-02-22,NA,Observational,NA,2000,"Active, not recruiting",Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.,2018-02-05T00:00:00Z,2025-04-30T00:00:00Z,2024-10-30T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT03599245,2023-10-25,2018-06-25,NA,Interventional,Phase 3,1500,"Active, not recruiting",This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2018-07-12T00:00:00Z,2025-03-11T00:00:00Z,2025-02-23T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT03626012,2022-01-13,2018-08-07,NA,Interventional,Phase 1,106,Completed,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",2018-09-10T00:00:00Z,2021-11-17T00:00:00Z,2021-11-17T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03650114,2023-09-29,2018-08-17,NA,Interventional,Phase 3,2060,Recruiting,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",2018-12-28T00:00:00Z,2028-09-07T00:00:00Z,2027-12-30T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT03655236,2023-07-24,2018-08-18,NA,Interventional,Phase 2,504,Recruiting,PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706,2019-02-18T00:00:00Z,2024-03-01T00:00:00Z,2024-03-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03661528,2023-09-11,2018-08-30,NA,Interventional,Phase 4,530,Completed,Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor,2019-06-06T00:00:00Z,2023-08-09T00:00:00Z,2023-05-27T00:00:00Z,FALSE,Randomized,Single,INDUSTRY,TRUE
NCT03689972,2023-08-17,2018-09-27,NA,Interventional,Phase 3,500,Completed,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-11-27T00:00:00Z,2023-07-24T00:00:00Z,2023-01-31T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT03709784,2022-09-19,2018-10-15,NA,Observational,NA,48,"Active, not recruiting",Spinraza in Adult Spinal Muscular Atrophy,2018-08-16T00:00:00Z,2024-01-01T00:00:00Z,2024-01-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT03737812,2021-12-15,2018-11-06,NA,Interventional,Phase 2,123,Completed,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis,2019-02-27T00:00:00Z,2021-08-30T00:00:00Z,2021-01-15T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT03737851,2021-12-01,2018-11-06,NA,Interventional,Phase 2,208,Completed,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis,2018-12-11T00:00:00Z,2021-09-09T00:00:00Z,2021-01-07T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT03750552,2022-08-18,2018-11-20,2022-07-20,Interventional,Phase 3,195,Completed,Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure,2019-01-24T00:00:00Z,2021-07-21T00:00:00Z,2021-07-21T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03770403,2023-06-21,2018-11-16,2023-06-21,Interventional,Phase 3,151,Completed,A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.,2019-03-01T00:00:00Z,2022-06-30T00:00:00Z,2022-06-23T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT03785678,2023-04-27,2018-12-19,NA,Interventional,Phase 3,452,Completed,Tenecteplase in Stroke Patients Between 4.5 and 24 Hours,2019-03-02T00:00:00Z,2023-02-28T00:00:00Z,2023-02-28T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03829657,2022-12-29,2019-01-10,2022-11-08,Interventional,Phase 3,203,Terminated,Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure,2019-02-22T00:00:00Z,2021-11-10T00:00:00Z,2021-11-10T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT03836716,2023-08-22,2019-02-07,2023-05-15,Interventional,Phase 3,120,Terminated,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,2019-09-19T00:00:00Z,2021-07-02T00:00:00Z,2021-07-02T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT03855137,2023-01-18,2019-02-25,2023-01-18,Interventional,Phase 3,778,Completed,"Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine",2019-03-11T00:00:00Z,2022-01-20T00:00:00Z,2022-01-20T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT03863080,2021-10-06,2019-02-20,NA,Interventional,Phase 2,17,Completed,A Study of RVT-1401 in Myasthenia Gravis (MG) Patients,2019-05-21T00:00:00Z,2020-12-21T00:00:00Z,2020-10-07T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03866603,2023-09-06,2019-03-01,NA,Observational,NA,25000,Recruiting,Rostock International Parkinson's Disease Study (ROPAD),2019-05-30T00:00:00Z,2025-12-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT03889249,2023-05-11,2019-03-20,NA,Interventional,Phase 3,1600,Completed,Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke,2019-12-10T00:00:00Z,2023-04-30T00:00:00Z,2022-04-26T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT03920293,2023-08-16,2019-04-16,2022-05-03,Interventional,Phase 3,175,Completed,Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis,2019-03-26T00:00:00Z,2023-05-25T00:00:00Z,2021-05-11T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE
NCT03936361,2023-07-10,2019-05-01,NA,Interventional,Phase 3,1456,Recruiting,Statins In Intracerbral Hemorrhage,2020-06-10T00:00:00Z,2026-12-31T00:00:00Z,2026-06-30T00:00:00Z,FALSE,Randomized,Single,OTHER,FALSE
NCT03943290,2022-09-13,2019-04-17,2021-03-11,Interventional,Phase 2,62,Terminated,Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX),2019-05-10T00:00:00Z,2020-03-11T00:00:00Z,2020-03-11T00:00:00Z,TRUE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT03950076,2023-01-23,2019-05-10,NA,Interventional,Phase 4,1200,Recruiting,EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF),2019-09-20T00:00:00Z,2024-04-01T00:00:00Z,2024-04-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT03970447,2023-11-01,2019-05-23,NA,Interventional,Phase 2/Phase 3,1030,Recruiting,A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma,2019-07-30T00:00:00Z,2028-06-01T00:00:00Z,2026-06-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE
NCT03971422,2023-08-22,2019-05-29,2023-07-27,Interventional,Phase 3,200,Completed,A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis,2019-06-03T00:00:00Z,2021-10-26T00:00:00Z,2021-08-31T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT03972306,2023-10-18,2019-05-29,NA,Interventional,Phase 1,134,"Active, not recruiting","A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",2019-08-12T00:00:00Z,2025-06-20T00:00:00Z,2023-01-27T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT03976349,2023-04-11,2019-06-04,NA,Interventional,Phase 1,82,Recruiting,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease",2019-08-12T00:00:00Z,2023-12-02T00:00:00Z,2023-12-02T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT04003974,2022-02-08,2019-06-25,NA,Interventional,Phase 2,80,Completed,Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD),2019-08-09T00:00:00Z,2021-01-28T00:00:00Z,2021-01-28T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04057898,2023-10-13,2019-08-06,NA,Interventional,Phase 2/Phase 3,230,Recruiting,Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS,2020-05-28T00:00:00Z,2024-12-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04095793,2022-11-07,2019-08-01,2022-11-07,Interventional,Phase 3,110,Terminated,Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure,2019-09-19T00:00:00Z,2021-11-12T00:00:00Z,2021-11-12T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT04115293,2023-05-02,2019-10-02,2022-12-19,Interventional,Phase 3,174,Completed,"Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis",2019-09-17T00:00:00Z,2021-12-30T00:00:00Z,2021-12-30T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04124965,2023-08-22,2019-10-11,2023-07-27,Interventional,Phase 3,71,Completed,"A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis",2019-10-29T00:00:00Z,2021-09-01T00:00:00Z,2021-09-01T00:00:00Z,TRUE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT04149457,2023-04-05,2019-10-28,NA,Interventional,Not Applicable,92,Recruiting,Improving Neurological Health in Aging Via Neuroplasticity-based Computerized Exercise,2021-07-16T00:00:00Z,2024-05-31T00:00:00Z,2024-05-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,FALSE
NCT04155606,2023-06-30,2019-11-05,NA,Interventional,Not Applicable,2000,Recruiting,Comprehensive Aneurysm Management Trial,2020-01-15T00:00:00Z,2036-01-01T00:00:00Z,2035-01-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE
NCT04164901,2023-07-07,2019-11-11,NA,Interventional,Phase 3,340,"Active, not recruiting",Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO),2020-01-05T00:00:00Z,2027-08-01T00:00:00Z,2024-10-01T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,TRUE
NCT04165824,2023-05-12,2019-11-13,2022-08-05,Interventional,Phase 3,185,Completed,Safety Study of Oral Edaravone Administered in Subjects With ALS,2019-11-18T00:00:00Z,2021-10-07T00:00:00Z,2021-10-07T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT04167527,2023-09-06,2019-11-15,NA,Interventional,Phase 2/Phase 3,200,Recruiting,Endovascular Therapy for Low NIHSS Ischemic Strokes,2020-09-05T00:00:00Z,2024-12-01T00:00:00Z,2024-12-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT04192955,2023-05-04,2019-11-28,NA,Interventional,Phase 3,440,Recruiting,Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms,2020-07-14T00:00:00Z,2024-12-01T00:00:00Z,2024-09-01T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,TRUE
NCT04225871,2023-08-03,2019-10-02,NA,Interventional,Phase 3,200,"Active, not recruiting",Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis,2019-12-23T00:00:00Z,2026-06-02T00:00:00Z,2026-06-02T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT04241068,2023-04-13,2020-01-22,NA,Interventional,Phase 3,1696,"Active, not recruiting","A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",2020-03-02T00:00:00Z,2025-02-03T00:00:00Z,2023-10-20T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT04248465,2022-12-15,2020-01-27,2022-09-22,Interventional,Phase 3,382,Terminated,An Efficacy and Safety Study of Ravulizumab in ALS Participants,2020-03-30T00:00:00Z,2021-10-17T00:00:00Z,2021-10-17T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04259255,2023-08-23,2020-01-27,NA,Observational,NA,300,"Active, not recruiting",Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS),2019-10-21T00:00:00Z,2024-03-01T00:00:00Z,2024-03-01T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT04261478,2022-11-08,2020-02-03,NA,Interventional,Not Applicable,458,Recruiting,Endovascular Acute Stroke Intervention - Tandem OCclusion Trial,2020-08-31T00:00:00Z,2027-03-01T00:00:00Z,2026-06-01T00:00:00Z,FALSE,Randomized,Single,OTHER,FALSE
NCT04288856,2023-04-13,2020-02-26,NA,Interventional,Phase 1,75,Terminated,"Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)",2020-04-28T00:00:00Z,2022-05-03T00:00:00Z,2022-05-03T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE
NCT04322149,2023-06-06,2020-03-20,2023-05-10,Interventional,Phase 2,54,Completed,Multiple Doses of AT-1501-A201 in Adults With ALS,2020-10-16T00:00:00Z,2022-03-24T00:00:00Z,2022-03-24T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE
NCT04338022,2023-10-02,2020-04-06,NA,Interventional,Phase 3,1124,"Active, not recruiting",Study of Evobrutinib in Participants With RMS (evolutionRMS 1),2020-06-12T00:00:00Z,2026-06-26T00:00:00Z,2023-10-02T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04349514,2023-08-20,2020-04-01,NA,Observational,NA,300,Recruiting,A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals With Friedreich Ataxia (TRACK-FA),2021-02-10T00:00:00Z,2025-08-01T00:00:00Z,2025-08-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT04411641,2023-02-09,2020-05-28,NA,Interventional,Phase 3,1131,"Active, not recruiting",Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),2020-09-24T00:00:00Z,2024-08-01T00:00:00Z,2024-08-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT04458051,2023-08-15,2020-07-01,NA,Interventional,Phase 3,990,Recruiting,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),2020-08-13T00:00:00Z,2024-08-01T00:00:00Z,2024-08-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT04462536,2023-09-08,2020-07-02,NA,Interventional,Phase 3,850,Completed,Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis,2020-12-06T00:00:00Z,2023-08-31T00:00:00Z,2023-08-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04477785,2023-08-15,2020-07-15,NA,Observational,NA,4500,Recruiting,PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort,2020-07-01T00:00:00Z,2033-12-01T00:00:00Z,2033-12-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT04494256,2023-10-03,2020-07-30,NA,Interventional,Phase 1/Phase 2,99,"Active, not recruiting","A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation",2020-09-28T00:00:00Z,2026-07-15T00:00:00Z,2026-07-15T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT04524273,2023-09-15,2020-08-10,NA,Interventional,Phase 3,270,Recruiting,Myasthenia Gravis Inebilizumab Trial,2020-08-30T00:00:00Z,2029-03-31T00:00:00Z,2024-10-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04539041,2023-10-11,2020-08-25,NA,Interventional,Phase 1,66,Recruiting,"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy",2021-02-16T00:00:00Z,2024-11-12T00:00:00Z,2024-11-12T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04544449,2023-09-11,2020-09-04,NA,Interventional,Phase 3,985,"Active, not recruiting",A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis,2020-10-26T00:00:00Z,2026-12-18T00:00:00Z,2026-01-16T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04548999,2023-11-01,2020-09-09,NA,Interventional,Phase 3,699,"Active, not recruiting","A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-12-03T00:00:00Z,2029-07-26T00:00:00Z,2025-11-12T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04569084,2023-10-26,2020-09-23,NA,Interventional,Phase 3,384,Terminated,Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS,2020-11-13T00:00:00Z,2023-09-29T00:00:00Z,2023-09-29T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04569435,2023-03-23,2020-09-23,NA,Interventional,Phase 2,24,Recruiting,Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS),2021-01-15T00:00:00Z,2024-01-01T00:00:00Z,2023-10-01T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT04577404,2023-10-26,2020-09-30,NA,Interventional,Phase 3,124,Completed,Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS),2020-10-29T00:00:00Z,2023-08-08T00:00:00Z,2023-08-08T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT04586023,2023-10-20,2020-10-08,NA,Interventional,Phase 3,736,Recruiting,Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),2021-03-24T00:00:00Z,2025-11-27T00:00:00Z,2025-10-02T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04619420,2023-11-07,2020-11-05,NA,Interventional,Phase 2,523,"Active, not recruiting",A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease,2021-01-06T00:00:00Z,2025-11-05T00:00:00Z,2025-03-07T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04635891,2022-12-12,2020-10-29,NA,Observational,NA,450,Recruiting,Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD),2020-12-15T00:00:00Z,2024-01-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT04642443,2023-09-25,2020-11-19,NA,Interventional,Not Applicable,450,Recruiting,Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage,2020-12-23T00:00:00Z,2024-09-30T00:00:00Z,2024-06-30T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,FALSE
NCT04650854,2023-11-02,2020-11-05,NA,Interventional,Phase 3,165,"Active, not recruiting",A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis,2021-02-03T00:00:00Z,2024-01-31T00:00:00Z,2024-01-31T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT04686136,2023-03-22,2020-12-21,NA,Interventional,Phase 3,596,"Active, not recruiting",A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine,2021-02-19T00:00:00Z,2024-09-13T00:00:00Z,2024-09-13T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT04747431,2023-11-02,2021-02-02,NA,Interventional,Phase 1/Phase 2,15,Recruiting,A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN),2021-09-14T00:00:00Z,2027-08-01T00:00:00Z,2024-08-01T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE
NCT04762758,2023-04-04,2021-02-17,NA,Interventional,Phase 3,350,"Active, not recruiting",Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients,2021-03-30T00:00:00Z,2024-03-31T00:00:00Z,2023-10-31T00:00:00Z,FALSE,Randomized,Double,OTHER,TRUE
NCT04768972,2023-09-14,2021-02-22,NA,Interventional,Phase 3,77,Recruiting,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)",2021-06-14T00:00:00Z,2028-03-01T00:00:00Z,2026-06-01T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04777331,2023-11-01,2021-02-26,NA,Interventional,Phase 2,586,"Active, not recruiting",A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease,2021-05-05T00:00:00Z,2026-11-27T00:00:00Z,2024-09-20T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04783935,2023-09-07,2021-03-03,NA,Interventional,Phase 4,219,"Active, not recruiting",Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),2021-03-10T00:00:00Z,2023-11-30T00:00:00Z,2023-11-30T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT04840823,2023-03-21,2021-03-29,NA,Interventional,Phase 1/Phase 2,36,"Active, not recruiting",Enoxacin for Amyotrophic Lateral Sclerosis (ALS),2021-03-26T00:00:00Z,2023-05-01T00:00:00Z,2023-05-01T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,FALSE
NCT04886518,2023-08-23,2021-05-10,NA,Interventional,Phase 2,30,"Active, not recruiting",Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1,2021-06-28T00:00:00Z,2023-10-01T00:00:00Z,2023-09-01T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04893083,2023-10-26,2021-05-12,NA,Observational,NA,65,Terminated,A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease,2021-06-28T00:00:00Z,2023-09-22T00:00:00Z,2023-06-30T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT04923984,2022-05-30,2021-06-07,NA,Interventional,Not Applicable,100,Recruiting,Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can),2021-05-01T00:00:00Z,2024-11-01T00:00:00Z,2024-03-01T00:00:00Z,FALSE,NA,None (Open Label),OTHER,FALSE
NCT04926818,2023-10-09,2021-06-14,NA,Interventional,Phase 3,180,Recruiting,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,2021-10-05T00:00:00Z,2029-06-01T00:00:00Z,2026-08-04T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04931862,2023-10-18,2021-06-11,NA,Interventional,Phase 1/Phase 2,35,Terminated,Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD),2021-06-28T00:00:00Z,2023-06-27T00:00:00Z,2023-06-27T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04935866,2022-08-16,2021-06-15,NA,Observational,NA,286,Recruiting,Optimal Brain Oxygenation in Neurologic Intensive Care Unit : The NeurO2 Study,2021-05-07T00:00:00Z,2025-07-01T00:00:00Z,2024-07-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT04936542,2023-10-31,2021-06-09,NA,Interventional,Phase 4,564,Recruiting,A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.,2021-06-23T00:00:00Z,2024-06-28T00:00:00Z,2024-06-28T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04944784,2023-04-12,2021-06-16,NA,Interventional,Phase 3,486,Terminated,A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS),2021-08-16T00:00:00Z,2023-03-31T00:00:00Z,2023-03-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT04948645,2023-01-20,2021-06-23,NA,Interventional,Phase 1,31,"Active, not recruiting",A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis,2021-09-22T00:00:00Z,2025-12-01T00:00:00Z,2023-01-12T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT04951622,2023-11-08,2021-06-30,NA,Interventional,Phase 3,198,Recruiting,A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis,2021-07-15T00:00:00Z,2026-04-17T00:00:00Z,2023-11-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT04963270,2023-10-31,2021-07-07,NA,Interventional,Phase 3,185,Recruiting,"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis",2021-10-19T00:00:00Z,2027-12-11T00:00:00Z,2024-01-31T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT04980495,2023-10-09,2021-07-19,NA,Interventional,Phase 3,69,"Active, not recruiting",An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis,2021-12-16T00:00:00Z,2025-11-03T00:00:00Z,2023-08-24T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE
NCT05021991,2023-10-16,2021-08-20,NA,Interventional,Phase 2,131,"Active, not recruiting",A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor,2021-10-14T00:00:00Z,2023-12-01T00:00:00Z,2023-02-09T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05039099,2023-08-02,2021-09-01,NA,Interventional,Phase 2,63,Recruiting,"A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)",2021-09-02T00:00:00Z,2025-01-18T00:00:00Z,2024-06-28T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT05054140,2023-01-31,2021-09-02,NA,Interventional,Phase 2,450,Recruiting,"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",2021-09-30T00:00:00Z,2024-07-28T00:00:00Z,2024-04-05T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT05061953,2023-03-01,2021-09-21,NA,Observational,NA,168,Recruiting,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,2021-10-18T00:00:00Z,2027-10-18T00:00:00Z,2027-10-18T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE
NCT05132569,2023-03-08,2021-11-12,NA,Interventional,Phase 3,6,Terminated,Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis,2021-12-03T00:00:00Z,2023-02-21T00:00:00Z,2023-02-21T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT05151172,2023-09-27,2021-11-25,NA,Interventional,Not Applicable,530,Recruiting,EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial),2022-04-15T00:00:00Z,2026-08-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE
NCT05151471,2023-10-26,2021-11-28,NA,Interventional,Phase 3,202,Terminated,Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS,2022-01-11T00:00:00Z,2023-09-29T00:00:00Z,2023-09-29T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05204017,2023-05-10,2021-11-29,NA,Observational,NA,150,Recruiting,"Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS",2021-09-12T00:00:00Z,2025-07-01T00:00:00Z,2024-01-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT05216250,2023-10-18,2021-10-01,NA,Interventional,Phase 2,174,Recruiting,Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor,2022-04-12T00:00:00Z,2025-02-27T00:00:00Z,2024-11-15T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT05231785,2023-10-20,2022-01-30,NA,Interventional,Phase 1,60,Recruiting,A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD,2022-02-04T00:00:00Z,2025-07-01T00:00:00Z,2025-07-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT05237284,2023-09-22,2022-02-02,NA,Interventional,Phase 2,305,"Active, not recruiting",Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS),2022-04-13T00:00:00Z,2025-07-24T00:00:00Z,2024-01-16T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT05269004,2023-10-06,2022-02-11,NA,Interventional,Phase 3,1300,"Active, not recruiting",A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,2022-05-03T00:00:00Z,2025-12-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT05269667,2023-11-06,2022-02-15,NA,Interventional,Phase 4,4,Terminated,A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention,2022-08-02T00:00:00Z,2023-10-26T00:00:00Z,2023-10-26T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE
NCT05271409,2023-10-25,2022-02-28,NA,Interventional,Phase 3,152,Recruiting,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease",2022-08-30T00:00:00Z,2028-12-31T00:00:00Z,2026-04-30T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE
NCT05348785,2023-10-11,2022-04-04,NA,Interventional,Phase 2,640,Recruiting,A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80,2022-04-19T00:00:00Z,2025-08-28T00:00:00Z,2025-08-15T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05349721,2023-10-11,2022-04-21,NA,Interventional,Phase 2,258,Recruiting,Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS,2022-05-15T00:00:00Z,2025-02-28T00:00:00Z,2024-07-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05397470,2023-09-27,2022-05-04,NA,Interventional,Phase 3,260,"Active, not recruiting",Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH),2022-06-16T00:00:00Z,2026-01-01T00:00:00Z,2024-10-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05399888,2023-10-25,2022-05-27,NA,Interventional,Phase 2,735,Recruiting,"A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into the Cerebrospinal Fluid of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age",2022-08-24T00:00:00Z,2026-12-14T00:00:00Z,2026-12-14T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05403541,2023-10-11,2022-05-26,NA,Interventional,Phase 3,210,Recruiting,Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis,2022-06-27T00:00:00Z,2025-04-01T00:00:00Z,2024-04-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT05407324,2023-10-25,2022-06-02,NA,Interventional,Phase 2,198,Recruiting,Dazucorilant in Patients With Amyotrophic Lateral Sclerosis,2022-11-15T00:00:00Z,2024-11-01T00:00:00Z,2024-05-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT05442775,2023-04-12,2022-06-16,NA,Interventional,Phase 3,72,Terminated,"A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)",2022-07-25T00:00:00Z,2023-03-31T00:00:00Z,2023-03-31T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT05602727,2023-10-20,2022-10-27,NA,Interventional,Phase 2,99,Terminated,Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008),2022-12-02T00:00:00Z,2023-09-27T00:00:00Z,2023-09-27T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE
NCT05633459,2023-10-19,2022-11-21,NA,Interventional,Phase 1,64,Recruiting,A Study Evaluating the Safety and Tolerability of QRL-201 in ALS,2022-12-16T00:00:00Z,2025-05-06T00:00:00Z,2025-05-06T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05686070,2023-11-08,2023-01-06,NA,Interventional,Phase 3,9300,Recruiting,A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack),2023-01-26T00:00:00Z,2025-10-10T00:00:00Z,2025-10-10T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05686551,2023-11-06,2022-12-16,NA,Interventional,Phase 2,300,Recruiting,"GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.",2023-02-03T00:00:00Z,2027-01-04T00:00:00Z,2025-01-03T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05704361,2023-10-11,2023-01-04,NA,Interventional,Phase 1,63,Recruiting,"A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis.",2021-08-11T00:00:00Z,2025-01-31T00:00:00Z,2025-01-31T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE
NCT05779813,2023-03-23,2023-02-27,NA,Observational,NA,200,Recruiting,Genetic Frontotemporal Dementia Initiative for Neurodevelopment,2023-03-01T00:00:00Z,2035-03-01T00:00:00Z,2033-03-01T00:00:00Z,FALSE,NA,NA,OTHER,FALSE
NCT05819359,2023-10-26,2023-04-06,NA,Interventional,Phase 2,237,Recruiting,"Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD",2023-03-31T00:00:00Z,2026-03-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT05826457,2023-04-20,2023-02-08,NA,Observational,NA,500,Recruiting,North American Prodromal Synucleinopathy Consortium Stage 2,2022-08-12T00:00:00Z,2025-05-01T00:00:00Z,2025-05-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE
NCT05908695,2023-11-08,2023-05-31,NA,Interventional,Phase 4,1312,Recruiting,An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease,2023-08-31T00:00:00Z,2029-12-01T00:00:00Z,2029-06-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE
NCT06038643,2023-10-29,2022-04-25,NA,Interventional,Not Applicable,80,Recruiting,Intergenerational Behavioral Intervention to Enhance Physical Activity in Older Adults at Risk for Alzheimer's Disease,2023-10-24T00:00:00Z,2024-05-30T00:00:00Z,2024-02-20T00:00:00Z,FALSE,Randomized,Double,OTHER,FALSE
